Healthcare systems are struggling to find solutions to the mounting pandemic of inequity of healthcare provision. Debilitating inequalities of access to care are spiralling, which is a critical barrier to delivery of equitable care. Solving health inequalities in healthcare does not wholly lie with any one stakeholder. Sustainable success and solutions will only be delivered through clarity of goals, innovative and inclusive community-based programmes, conscious collaborations between the public and private sector, and accelerated, measured impact.
Porter Novelli convened a session: Delivering EU health equity: a 2030 ambition which brought together eminent experts to discuss barriers and benchmarks to support improved equitable access to healthcare for at-risk communities – unlocking sustainable health outcomes with durable policies to address health inequalities.
Also unveiled during the debate was data from a global survey (conducted with Hall & Partners) of more than 500 healthcare professionals (HCPs) and payers in the US, UK and Germany. It revealed that the pharmaceutical industry is expected to play a central role in working towards this ambition.
The EHFG is an independent, non-partisan organisation, founded in 1998 as a European health policy platform, which has since grown far beyond traditional health policy spaces. Their aim is to provide a neutral and inclusive platform for the discussion and advancement of health, solidarity and equity in the EU and beyond, and their founding principle is the equal representation of all stakeholders.
About the research
We commissioned the survey, tracking purpose and health equity beliefs of HCPs and payers in the US, UK and Germany using a robust sample of approximately 460 HCPs and 75 payers.
- HCPs included three specialties: oncology, neurology and infectious diseases/immunology.
- Payors were formulary decision makers at organisations responsible for processing patient eligibility, enrolment claims and payment.
Fieldwork took place between July – August 2022.
KEY STAT: Data shows that over three quarters (76%) of HCPs and 89% of payers agree that pharmaceutical companies have a responsibility to overcome health equity challenges among the critical patient populations (relevant to unmet community needs at a disease level)
What happened at EHFG 2022?
Panellists were invited to reflect on real-life learnings, including those from the COVID-19 pandemic, and debate what a potential 2030 roadmap to success looks like for the EU Member States. What are the building blocks policymakers and system funders need to have in place to be able to provide and facilitate impact from a consortium of players? How can we incentivise collective and innovative thinking? What do we expect specifically from the pharmaceutical sector?
- MICHAEL MARMOT, Director, The UCL Institute of Health Equity
- DENIS ONYANGO, Head of Programmes, African Advocacy Foundation
- CAROLINE COSTONGS, Director, EuroHealthNet
- ANCA TOMA, Executive Director, European Patients Forum
- RICARDO BAPTISTA LEITE, Member of Parliament, Portugal
- ALEXANDRA TAMAS, Director Public Affairs, European Federation of Pharmaceutical Industries & Associations
- ISABEL DE LA MATA, Principal Advisor for Health and Crisis Management, European Commission Directorate-General for Health and Food Safety
- CARLO MARTUSCELLI, Reporter, POLITICO
As a next step, Omnicom Public Relations Group (OPRG) will host a global virtual panel on November 1, which will set action, prioritise, define communicators’ roles and raise never-before-discussed dialogue. OPRG is actively listening to communities, believes earning trust must be a priority, and will launch a global study of communities to uncover any gaps, to debut in early 2023.
Why work with us?
Over 45 years ago, Porter Novelli opened its doors – and people’s eyes and minds – to the idea that the art of communication could advance society.
Today, as an advisory, consulting and communications firm, our purpose is to help our clients achieve better business results, improve their relevance and have a positive impact on the greater good. In a world of rapidly changing expectations, we understand the healthcare sector is at the forefront of delivering system impact – and has been for decades. Now, faced with even greater global challenges, healthcare companies are expected to lead more and solve more. We find new ways for clients to unlock resilient, precision impact to benefit both society, company and brand.